The effect of age on the response to the pneumococcal polysaccharide vaccine

BMC Infectious Diseases

Volumn 10, Issue , 2010, Pages

  Lee, Hyunju ^a   Nahm, Moon H ^b   Kim, Kyung Hyo ^a  

^a Ewha Womans University School of Medicine   (South Korea)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; OPSONIN; PNEUMO23; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

AGE DISTRIBUTION; AGED; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NORMAL HUMAN; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SEROTYPE; SEX DIFFERENCE; STREPTOCOCCUS PNEUMONIA; VACCINATION; ADULT; AGE; BLOOD; CLINICAL TRIAL; IMMUNOLOGY; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTION; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; OPSONIN PROTEINS; PHAGOCYTOSIS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952300034     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-10-60     Document Type: Article

References (33)

1. Centers for Disease Control and Prevention (CDC) 23-valent pneumococcal polysaccharide vaccine. WHO position paper. Wkly Epidemiol Rec 2008, 83:373-384. Centers for Disease Control and Prevention (CDC).
2. Fedson DS. The clinical effectiveness of pneumococcal vaccination: a brief review. Vaccine 1999, 17(Suppl 1):85-90.
3. Shapiro ED, Berg AT, Austrian R, Schroeder D, Parcells V, Margolis A, Adair RK, Clemens JD. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N Engl J Med 1991, 325:1453-1460.
4. Moberley SA, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 2008, CD000422.
5. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006, 13:165-169. 10.1128/CVI.13.2.165-169.2006, 1391943, 16467321.
6. Romero-Steiner S, Musher DM, Cetron MS, Pais LB, Groover JE, Fiore AE, Plikaytis BD, Carlone GM. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin Infect Dis 1999, 29:281-288. 10.1086/520200, 10476727.
7. Sankilampi U, Honkanen PO, Bloigu A, Herva E, Leinonen M. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1996, 173:387-393.
8. Rubins JB, Puri AK, Loch J, Charboneau D, MacDonald R, Opstad N, Janoff EN. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J Infect Dis 1998, 178:431-440.
9. Rubins JB, Alter M, Loch J, Janoff EN. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999, 67:5979-5984. 96983, 10531257.
10. Concepcion NF, Frasch CE. Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol 2001, 8:266-272. 96047, 11238206.
11. Coughlin RT, White AC, Anderson CA, Carlone GM, Klein DL, Treanor J. Characterization of pneumococcal specific antibodies in healthy unvaccinated adults. Vaccine 1998, 16:1761-1767. 10.1016/S0264-410X(98)00139-X, 9778753.
12. Yu X, Sun Y, Frasch C, Concepcion N, Nahm MH. Pneumococcal capsular polysaccharide preparations may contain non-C-polysaccharide contaminants that are immunogenic. Clin Diagn Lab Immunol 1999, 6:519-524. 95719, 10391854.
13. Wernette CM, Frasch CE, Madore D, Carlone G, Goldblatt D, Plikaytis B, Benjamin W, Quataert SA, Hildreth S, Sikkema DJ, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol 2003, 10:514-519. 164258, 12853378.
14. Schenkein JG, Park S, Nahm MH. Pneumococcal vaccination in older adults induces antibodies with low opsonic capacity and reduced antibody potency. Vaccine 2008, 26:5521-5526. 10.1016/j.vaccine.2008.07.071, 2574975, 18706464.
15. Kim KH, Yu J, Nahm MH. Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies. Clin Diagn Lab Immunol 2003, 10:616-621. 164251, 12853394.
16. Romero-Steiner S, Libutti D, Pais LB, Dykes J, Anderson P, Whitin JC, Keyserling HL, Carlone GM. Standardization of an opsonophagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells. Clin Diagn Lab Immunol 1997, 4:415-422. 170543, 9220157.
17. Weksler ME, Szabo P. The effect of age on the B-cell repertoire. J Clin Immunol 2000, 20:240-249. 10.1023/A:1006659401385, 10939711.
18. Kline GH, Hayden TA, Klinman NR. B cell maintenance in aged mice reflects both increased B cell longevity and decreased B cell generation. J Immunol 1999, 162:3342-3349.
19. Musher DM, Chapman AJ, Goree A, Jonsson S, Briles D, Baughn RE. Natural and vaccine-related immunity to Streptococcus pneumoniae. J Infect Dis 1986, 154:245-256.
20. Zheng B, Han S, Takahashi Y, Kelsoe G. Immunosenescence and germinal center reaction. Immunol Rev 1997, 160:63-77. 10.1111/j.1600-065X.1997.tb01028.x, 9476666.
21. Fedson DS, Musher DM. Pneumococcal Polysaccharide. Vaccines 2004, 529-588. Philadelphia: Saunders, Plotkin SA, Orenstein WA, 4.
22. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007, 45:1225-1233. 10.1128/JCM.02199-06, 1865839, 17267625.
23. Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the Prevalence of the Newly Discovered Pneumococcal Serotype 6C in the Nasopharynx after Introduction of Pneumococcal Conjugate Vaccine. J Infect Dis 2009, 199:320-5. 10.1086/596064, 2743180, 19099489.
24. Park IH, Moore MR, Treanor JJ, Pelton SI, Pilishvili T, Beall B, Shelly MA, Mahon BE, Nahm MH. Differential Effects of Pneumococcal Vaccines against Serotypes 6A and 6C. J Infect Dis 2008, 198:1818-1822. 10.1086/593339, 18983249.
25. Musher DM, Groover JE, Graviss EA, Baughn RE. The lack of association between aging and postvaccination levels of IgG antibody to capsular polysaccharides of Streptococcus pneumoniae. Clin Infect Dis 1996, 22:165-167.
26. Konradsen HB. Quantity and avidity of pneumococcal antibodies before and up to five years after pneumococcal vaccination of elderly persons. Clin Infect Dis 1995, 21:616-620.
27. Carson PJ, Nichol KL, O'Brien J, Hilo P, Janoff EN. Immune function and vaccine responses in healthy advanced elderly patients. Arch Intern Med 2000, 160:2017-2024. 10.1001/archinte.160.13.2017, 10888975.
28. Burton RL, Nahm MH. Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol 2006, 13:1004-1009. 10.1128/CVI.00112-06, 1563573, 16960111.
29. Martinez JE, Clutterbuck EA, Li H, Romero-Steiner S, Carlone GM. Evaluation of multiplex flow cytometric opsonophagocytic assays for determination of functional anticapsular antibodies to Streptococcus pneumoniae. Clin Vaccine Immunol 2006, 13:459-466. 10.1128/CVI.13.4.459-466.2006, 1459634, 16603613.
30. Romero-Steiner S, Frasch CE, Carlone G, Fleck RA, Goldblatt D, Nahm MH. Use of opsonophagocytosis for serological evaluation of pneumococcal vaccines. Clin Vaccine Immunol 2006, 13:165-169. 10.1128/CVI.13.2.165-169.2006, 1391943, 16467321.
31. Henckaerts I, Durant N, De Grave D, Schuerman L, Poolman J. Validation of a routine opsonophagocytosis assay to predict invasive pneumococcal disease efficacy of conjugate vaccine in children. Vaccine 2007, 25:2518-2527. 10.1016/j.vaccine.2006.09.029, 17034907.
32. Ogilvie I, Khoury AE, Cui Y, Dasbach E, Grabenstein JD, Goetghebeur M. Cost-effectiveness of pneumococcal polysaccharide vaccination in adults: A systematic review of conclusions and assumptions. Vaccine 2009, 27:4891-904. 10.1016/j.vaccine.2009.05.061, 19520205.
33. Smith KJ, Zimmerman RK, Nowalk MP, Roberts MS. Age, revaccination, and tolerance effects on pneumococcal vaccination strategies in the elderly: A cost-effectiveness analysis. Vaccine 2009, 27:3159-3164. 10.1016/j.vaccine.2009.03.059, 19446186.